Owing to the high amino acid similarities in the kinase domains of ALK and ROS1, several ALK-TKIs, such as crizotinib or lorlatinib, have antitumor effects on ROS1-rearranged cell lines (57) and showed clinical benefits in patients with ROS1-positive NSCLC (58, 59). Here, ROS1 is linked to non-small cell lung carcinoma.